成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Membrane Transporter/Ion Channel
  3. SGLT
  4. Dapagliflozin

Dapagliflozin  (Synonyms: 達(dá)格列凈; BMS-512148)

目錄號(hào): HY-10450 純度: 99.97%
COA 產(chǎn)品使用指南

Dapagliflozin (BMS-512148) 是一種競(jìng)爭(zhēng)性葡萄糖協(xié)同轉(zhuǎn)運(yùn)蛋白2 (SGLT2) 抑制劑，可導(dǎo)致尿液中葡萄糖的排泄，用于糖尿病 (DM) 的研究。Dapagliflozin 誘導(dǎo) HIF1 表達(dá)并減輕腎臟 IR 損傷。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Dapagliflozin Chemical Structure

Dapagliflozin Chemical Structure

CAS No. : 461432-26-8

1.  客戶(hù)無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶(hù)。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥825
In-stock
5 mg ￥750
In-stock
10 mg ￥1100
In-stock
50 mg ￥2750
In-stock
100 mg ￥4500
In-stock
200 mg   詢(xún)價(jià)  
500 mg   詢(xún)價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Dapagliflozin:

MCE 顧客使用本產(chǎn)品發(fā)表的 38 篇科研文獻(xiàn)

WB
Cell Viability Assay
IF

    Dapagliflozin purchased from MCE. Usage Cited in: Life Sci. 2023 Apr 4;121671.  [Abstract]

    Dapagliflozin (DAPA; 10, 20 μM; 24 h) significantly reverses the decrease in cell viability caused by high glucose in HK-2 cells.

    Dapagliflozin purchased from MCE. Usage Cited in: Life Sci. 2023 Apr 4;121671.  [Abstract]

    Dapagliflozin (DAPA; 10 μM; 24 hours) significantly reduces the high glucose-induced increase in YAP/TAZ expression in HK-2 cells.

    Dapagliflozin purchased from MCE. Usage Cited in: Life Sci. 2023 Apr 4;121671.  [Abstract]

    Dapagliflozin (DAPA; 10 μM; 24 hours) significantly decreases the expression of YAP/TAZ and increases the ratios of p-YAP/YAP and pTAZ/TAZ under high glucose conditions in HK-2 cells.

    Dapagliflozin purchased from MCE. Usage Cited in: EBioMedicine. 2022, 86: 104342.

    Dapagliflozin increases the LC3-II to LC3-I expression ratio in the liver.

    Dapagliflozin purchased from MCE. Usage Cited in: Biochem Pharmacol. 2018 Jun;152:45-59.  [Abstract]

    Effects of Dapagliflozin and Empagliflozin on p62 expression in LPS-untreated and LPS-treated RAW264.7 cells.

    Dapagliflozin purchased from MCE. Usage Cited in: Cell Physiol Biochem. 2018;45(5):1747-1758.  [Abstract]

    The expression of IRS1 significantly decreases. The phosphorylation levels of Akt1, Akt2, and S6 are significantly reduced in livers of db/db mice.

    查看 SGLT 亞型特異性產(chǎn)品:

    • 生物活性

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine[1]. Dapagliflozin induces HIF1 expression and attenuates renal IR injury[2].

    IC50 & Target

    SGLT2

     

    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    CHO IC50
    0.004 μM
    Compound: 2
    Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of [14C]-alpha-methyl-D-glucopyranoside transport after 60 mins by scintillation counting
    Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of [14C]-alpha-methyl-D-glucopyranoside transport after 60 mins by scintillation counting
    		[PMID: 21398124]
    CHO IC50
    0.022 μM
    Compound: 2
    Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of [14C]-alpha-methyl-D-glucopyranoside transport after 60 mins by scintillation counting in presence of 100% plasma
    Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of [14C]-alpha-methyl-D-glucopyranoside transport after 60 mins by scintillation counting in presence of 100% plasma
    		[PMID: 21398124]
    CHO IC50
    0.37 μM
    Compound: 2
    Inhibition of human SGLT1 expressed in CHO cells assessed as inhibition of [14C]-alpha-methyl-D-glucopyranoside transport after 60 mins by scintillation counting
    Inhibition of human SGLT1 expressed in CHO cells assessed as inhibition of [14C]-alpha-methyl-D-glucopyranoside transport after 60 mins by scintillation counting
    		[PMID: 21398124]
    CHO IC50
    0.38 μM
    Compound: 2
    Inhibition of SGLT6 expressed in CHO cells assessed as inhibition of [14C]-alpha-methyl-D-glucopyranoside transport after 60 mins by scintillation counting
    Inhibition of SGLT6 expressed in CHO cells assessed as inhibition of [14C]-alpha-methyl-D-glucopyranoside transport after 60 mins by scintillation counting
    		[PMID: 21398124]
    CHO IC50
    0.49 nM
    Compound: 1
    Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting
    Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting
    		[PMID: 24900297]
    CHO IC50
    0.49 nM
    Compound: Dapagliflozin
    Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting
    Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting
    		[PMID: 21906953]
    CHO IC50
    0.49 nM
    Compound: 1
    Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of [14C]alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting
    Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of [14C]alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting
    		[PMID: 21193308]
    CHO IC50
    0.49 nM
    Compound: 1
    Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting
    Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting
    		[PMID: 20434909]
    CHO IC50
    0.49 nM
    Compound: 9
    Inhibition of human recombinant SGLT2 expressed in CHO cells by liquid scintillation counting
    Inhibition of human recombinant SGLT2 expressed in CHO cells by liquid scintillation counting
    		[PMID: 20181486]
    CHO IC50
    0.49 nM
    Compound: 1
    Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counter
    Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counter
    		[PMID: 21514014]
    CHO IC50
    1.3 nM
    Compound: 4
    Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]methyl-alpha-D-glucopyranoside uptake after 45 mins
    Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]methyl-alpha-D-glucopyranoside uptake after 45 mins
    		[PMID: 22889351]
    CHO IC50
    1.35 nM
    Compound: Dapagliflozin
    Inhibition of human SGLT2 expressed in CHO cells assessed as reduction of [14C]-labeled AMG after 2 hrs by liquid scintillation counting
    Inhibition of human SGLT2 expressed in CHO cells assessed as reduction of [14C]-labeled AMG after 2 hrs by liquid scintillation counting
    		[PMID: 21868239]
    CHO IC50
    1.35 nM
    Compound: 1
    Inhibition of human SGLT2 expressed in CHO cells using methyl-alpha-D-glucopyranoside by liquid scintillation counting
    Inhibition of human SGLT2 expressed in CHO cells using methyl-alpha-D-glucopyranoside by liquid scintillation counting
    		[PMID: 21592794]
    CHO IC50
    1.4 nM
    Compound: 2
    Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of sodium-dependent methyl-alpha-D-[U-14C]glucopyranoside uptake after 2 hrs
    Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of sodium-dependent methyl-alpha-D-[U-14C]glucopyranoside uptake after 2 hrs
    		[PMID: 20149653]
    CHO IC50
    1200 nM
    Compound: 2
    Inhibition of human SGLT1 expressed in CHO cells assessed as inhibition of sodium-dependent methyl-alpha-D-[U-14C]glucopyranoside uptake after 2 hrs
    Inhibition of human SGLT1 expressed in CHO cells assessed as inhibition of sodium-dependent methyl-alpha-D-[U-14C]glucopyranoside uptake after 2 hrs
    		[PMID: 20149653]
    CHO EC50
    3 nM
    Compound: 5
    Inhibition of human SGLT2 expressed in CHO cells assessed as sodium-dependent [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting
    Inhibition of human SGLT2 expressed in CHO cells assessed as sodium-dependent [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting
    		[PMID: 21128592]
    CHO IC50
    3 nM
    Compound: Dapagliflozin
    Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of [14C]-Glucose uptake using [14C]-methyl glucopyranoside after 60 mins by microbeta plate counting
    Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of [14C]-Glucose uptake using [14C]-methyl glucopyranoside after 60 mins by microbeta plate counting
    		[PMID: 21565497]
    CHO EC50
    428.5 nM
    Compound: 5
    Inhibition of human SGLT1 expressed in CHO cells assessed as sodium-dependent [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting
    Inhibition of human SGLT1 expressed in CHO cells assessed as sodium-dependent [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting
    		[PMID: 21128592]
    CHO IC50
    5 nM
    Compound: 12
    Competitive inhibition of full-length human SGLT2 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by scintillation counting
    Competitive inhibition of full-length human SGLT2 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by scintillation counting
    		[PMID: 25650254]
    CHO IC50
    800 nM
    Compound: 4
    Inhibition of human SGLT1 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]methyl-alpha-D-glucopyranoside uptake after 45 mins
    Inhibition of human SGLT1 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]methyl-alpha-D-glucopyranoside uptake after 45 mins
    		[PMID: 22889351]
    CHO-K1 IC50
    1 nM
    Compound: 1
    Inhibition of human SGLT2 expressed in CHOK1 cells assessed as inhibition of [14C]-AMG uptake after 3 hrs by microbeta scintillation counting analysis
    Inhibition of human SGLT2 expressed in CHOK1 cells assessed as inhibition of [14C]-AMG uptake after 3 hrs by microbeta scintillation counting analysis
    		[PMID: 24842618]
    CHO-K1 IC50
    1.3 nM
    Compound: 3
    Inhibition of human SGLT2 expressed in CHO-K1 cells by [14C]AMG uptake assay
    Inhibition of human SGLT2 expressed in CHO-K1 cells by [14C]AMG uptake assay
    		[PMID: 22652255]
    CHO-K1 EC50
    2.4 nM
    Compound: 12
    Inhibition of human SGLT2 expressed in CHO-K1 cells incubated for 120 mins at 37 degC by [14C]-AMG uptake assay
    Inhibition of human SGLT2 expressed in CHO-K1 cells incubated for 120 mins at 37 degC by [14C]-AMG uptake assay
    		[PMID: 22818040]
    CHO-K1 EC50
    593 nM
    Compound: 12
    Inhibition of human SGLT1 expressed in CHO-K1 cells incubated for 120 mins at 37 degC by [14C]-AMG uptake assay
    Inhibition of human SGLT1 expressed in CHO-K1 cells incubated for 120 mins at 37 degC by [14C]-AMG uptake assay
    		[PMID: 22818040]
    CHO-K1 IC50
    800 nM
    Compound: 3
    Inhibition of human SGLT1 expressed in CHO-K1 cells by [14C]AMG uptake assay
    Inhibition of human SGLT1 expressed in CHO-K1 cells by [14C]AMG uptake assay
    		[PMID: 22652255]
    CHO-K1 IC50
    891 nM
    Compound: 1
    Inhibition of human SGLT1 expressed in CHOK1 cells assessed as inhibition of [14C]-AMG uptake after 3 hrs by microbeta scintillation counting analysis
    Inhibition of human SGLT1 expressed in CHOK1 cells assessed as inhibition of [14C]-AMG uptake after 3 hrs by microbeta scintillation counting analysis
    		[PMID: 24842618]
    COS-7 IC50
    0.89 μM
    Compound: 1
    Inhibition of human SGLT1 expressed in african green monkey COS7 cells assessed as inhibition of [14C]alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting
    Inhibition of human SGLT1 expressed in african green monkey COS7 cells assessed as inhibition of [14C]alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting
    		[PMID: 20576578]
    COS-7 IC50
    0.89 μM
    Compound: 2
    Inhibition of human SGLT1 transfected in COS-7 cells assessed as AMG uptake after 2 hrs by scintillation counting
    Inhibition of human SGLT1 transfected in COS-7 cells assessed as AMG uptake after 2 hrs by scintillation counting
    		[PMID: 19896374]
    COS-7 IC50
    3.2 nM
    Compound: 1
    Inhibition of human SGLT2 expressed in african green monkey COS7 cells assessed as inhibition of [14C]-methyl-alpha-D-glucopyranoside uptake after 2 hrs by scintillation counting in presence of 25 % human plasma
    Inhibition of human SGLT2 expressed in african green monkey COS7 cells assessed as inhibition of [14C]-methyl-alpha-D-glucopyranoside uptake after 2 hrs by scintillation counting in presence of 25 % human plasma
    		[PMID: 21737266]
    COS-7 IC50
    885 nM
    Compound: 1
    Inhibition of human SGLT1 expressed in african green monkey COS7 cells assessed as methyl-alpha-D-[U-14C]glucopyranoside uptake by scintillation counting
    Inhibition of human SGLT1 expressed in african green monkey COS7 cells assessed as methyl-alpha-D-[U-14C]glucopyranoside uptake by scintillation counting
    		[PMID: 19700318]
    HEK293 IC50
    0.0008 μM
    Compound: 4a
    Inhibition of human SGLT2 expressed in HEK293 cells assessed as reduction in 2-deoxyglucose uptake pretreated for 10 mins followed by 2-deoxyglucose addition in presence of sodium buffer measured after 1 hr by resazurin dye based fluorescence assay
    Inhibition of human SGLT2 expressed in HEK293 cells assessed as reduction in 2-deoxyglucose uptake pretreated for 10 mins followed by 2-deoxyglucose addition in presence of sodium buffer measured after 1 hr by resazurin dye based fluorescence assay
    		[PMID: 28098449]
    HEK293 IC50
    1.8 μM
    Compound: 4a
    Inhibition of human SGLT1 expressed in HEK293 cells assessed as reduction in 2-deoxyglucose uptake pretreated for 10 mins followed by 2-deoxyglucose addition in presence of sodium buffer measured after 1 hr by resazurin dye based fluorescence assay
    Inhibition of human SGLT1 expressed in HEK293 cells assessed as reduction in 2-deoxyglucose uptake pretreated for 10 mins followed by 2-deoxyglucose addition in presence of sodium buffer measured after 1 hr by resazurin dye based fluorescence assay
    		[PMID: 28098449]
    HEK293 IC50
    3100 nM
    Compound: 1
    Inhibition of human SGLT1 expressed in human 293 cells assessed as inhibition of [14C]-methyl-alpha-D-glucopyranoside uptake after 1.5 hrs by scintillation counting in presence of 25 % human plasma
    Inhibition of human SGLT1 expressed in human 293 cells assessed as inhibition of [14C]-methyl-alpha-D-glucopyranoside uptake after 1.5 hrs by scintillation counting in presence of 25 % human plasma
    		[PMID: 21737266]
    HEK293 IC50
    6.7 nM
    Compound: 1
    Inhibition of human SGLT2 expressed in HEK293 cells assessed as inhibition of [14C]alpha-methyl-D-glucopyranoside uptake after 1.5 hrs by liquid scintillation counting
    Inhibition of human SGLT2 expressed in HEK293 cells assessed as inhibition of [14C]alpha-methyl-D-glucopyranoside uptake after 1.5 hrs by liquid scintillation counting
    		[PMID: 20576578]
    NIH3T3 IC50
    12.3 μM
    Compound: 2
    Inhibition of human full length SGLT1 expressed in NIH3T3 cells measured after 1 hr in presence of [14C]-methyl-alpha -D-glucopyranoside by scintillation counter method
    Inhibition of human full length SGLT1 expressed in NIH3T3 cells measured after 1 hr in presence of [14C]-methyl-alpha -D-glucopyranoside by scintillation counter method
    		[PMID: 31325786]
    NIH3T3 IC50
    8.3 nM
    Compound: 2
    Inhibition of human full length SGLT2 expressed in NIH3T3 cells measured after 1 hr in presence of [14C]-methyl-alpha -D-glucopyranoside by scintillation counter method
    Inhibition of human full length SGLT2 expressed in NIH3T3 cells measured after 1 hr in presence of [14C]-methyl-alpha -D-glucopyranoside by scintillation counter method
    		[PMID: 31325786]
    體外研究
    (In Vitro)

    Dapagliflozin (0-10 μM；24 小時(shí)) 以劑量依賴(lài)性方式顯著增加缺氧 HK2 細(xì)胞中的細(xì)胞存活率[2]。
    Dapagliflozin (0-10 μM；2 小時(shí)) 增加缺氧 HK2 細(xì)胞中 HIF1 表達(dá)，增加 AMPK 和 EKR 磷酸化，但對(duì)常氧 HK2 細(xì)胞中 AMPK 和 ERK 磷酸化沒(méi)有影響[2]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Viability Assay[1]

    Cell Line: Hypoxic HK2 cells
    Concentration: 0 μM, 1 μM, 2 μM, 5 μM, 10 μM
    Incubation Time: 24 hours
    Result: Improved the cell viability in a dose-dependent manner compared with control cells.

    Western Blot Analysis[1]

    Cell Line: Hypoxic HK2 cells, Normoxic HK2 cells
    Concentration: 0 μM, 1 μM, 2 μM, 5 μM, 10 μM
    Incubation Time: 24 hours
    Result: Induced HIF1 expression in hypoxic and normoxic HK2 cells.
    體內(nèi)研究
    (In Vivo)

    Dapagliflozin（口服；10 mg/kg）可導(dǎo)致 SGLT2i 小鼠尿糖顯著增加，通過(guò)降低交感神經(jīng)活動(dòng)抑制 BAT 產(chǎn)熱，并增強(qiáng)肝臟糖異生和糖原分解[3]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    分子量

    408.87

    Formula

    C21H25ClO6
    CAS 號(hào)
    性狀

    固體

    顏色

    White to off-white

    中文名稱(chēng)

    達(dá)格列凈；達(dá)帕格列凈；達(dá)格列嗪
    運(yùn)輸條件

    Room temperature in continental US; may vary elsewhere.
    儲(chǔ)存方式

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    溶解性數(shù)據(jù)
    細(xì)胞實(shí)驗(yàn)： 

    DMSO 中的溶解度 : ≥ 100 mg/mL (244.58 mM; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開(kāi)封的 DMSO)

    H2O 中的溶解度 : 50 mg/mL (122.29 mM; 超聲助溶)

    * "≥" means soluble, but saturation unknown.

    配制儲(chǔ)備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 2.4458 mL 12.2288 mL 24.4577 mL
    5 mM 0.4892 mL 2.4458 mL 4.8915 mL
    查看完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

    * 備注：如您選擇水作為儲(chǔ)備液，請(qǐng)稀釋至工作液后，再用 0.22 μm 的濾膜過(guò)濾除菌后使用。

    • 摩爾計(jì)算器

    • 稀釋計(jì)算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動(dòng)物實(shí)驗(yàn)：

    請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
    ——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶

    • 方案 一

      請(qǐng)依序添加每種溶劑： 5% DMSO    40% PEG300    5% Tween-80    50% Saline

      Solubility: ≥ 2.5 mg/mL (6.11 mM); 澄清溶液

    • 方案 二

      請(qǐng)依序添加每種溶劑： 5% DMSO    95% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (6.11 mM); 澄清溶液

    以下溶解方案，請(qǐng)直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶。

    • 方案 一

      請(qǐng)依序添加每種溶劑： PBS

      Solubility: 33.33 mg/mL (81.52 mM); 澄清溶液; 超聲助溶 (<60°C)

    動(dòng)物溶解方案計(jì)算器
    請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

    給藥劑量

    mg/kg

    動(dòng)物的平均體重

    g

    每只動(dòng)物的給藥體積

    μL

    動(dòng)物數(shù)量

    只
    由于實(shí)驗(yàn)過(guò)程有損耗，建議您多配一只動(dòng)物的量
    計(jì)算結(jié)果
    工作液所需濃度 : mg/mL
    該產(chǎn)品水溶性佳，請(qǐng)具體參考實(shí)測(cè) 水 / PBS / Saline 中的溶解度數(shù)據(jù)。
    您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
    純度 & 產(chǎn)品資料

    純度: 99.97%

    參考文獻(xiàn)

    完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 2.4458 mL 12.2288 mL 24.4577 mL 61.1441 mL
    5 mM 0.4892 mL 2.4458 mL 4.8915 mL 12.2288 mL
    10 mM 0.2446 mL 1.2229 mL 2.4458 mL 6.1144 mL
    15 mM 0.1631 mL 0.8153 mL 1.6305 mL 4.0763 mL
    20 mM 0.1223 mL 0.6114 mL 1.2229 mL 3.0572 mL
    25 mM 0.0978 mL 0.4892 mL 0.9783 mL 2.4458 mL
    30 mM 0.0815 mL 0.4076 mL 0.8153 mL 2.0381 mL
    40 mM 0.0611 mL 0.3057 mL 0.6114 mL 1.5286 mL
    50 mM 0.0489 mL 0.2446 mL 0.4892 mL 1.2229 mL
    60 mM 0.0408 mL 0.2038 mL 0.4076 mL 1.0191 mL
    80 mM 0.0306 mL 0.1529 mL 0.3057 mL 0.7643 mL
    100 mM 0.0245 mL 0.1223 mL 0.2446 mL 0.6114 mL

    * 備注：如您選擇水作為儲(chǔ)備液，請(qǐng)稀釋至工作液后，再用 0.22 μm 的濾膜過(guò)濾除菌后使用。

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱(chēng)：

    		  

    * 需求量：

    * 客戶(hù)姓名：

    		 

    * Email：

    * 電話(huà)：

    		 

    * 公司或機(jī)構(gòu)名稱(chēng)：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱(chēng)：
    Dapagliflozin
    目錄號(hào)：
    HY-10450
    需求量：